Literature DB >> 19690026

First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer.

Elisabeth Miot-Noirault1, François Gouin, Aurélien Vidal, Maryse Rapp, Jean Maublant, Serge Askienazy, Jean-Michel Chezal, Dominique Heymann, Françoise Redini, Nicole Moins.   

Abstract

UNLABELLED: This study on a rat model of grade II chondrosarcoma aimed to determine whether the radiotracer N-(triethylammonium)-3-propyl-[15]ane-N5 radiolabeled with (99m)Tc ((99m)Tc-NTP 15-5), which binds to cartilage proteoglycans, has pathophysiologic validity for in vivo imaging of cartilage tumoral tissue.
METHODS: We used 2 experimental approaches with the Swarm chondrosarcoma rat model: that is, a primary paratibial location and local recurrence after intralesional curettage. (99m)Tc-NTP 15-5 scintigraphy and (99m)Tc-hydroxymethylenediphosphonate ((99m)Tc-HMDP) scanning were performed at regular intervals during 50 d after tumor implantation in a paratibial location (primary model; n = 12 animals) and after intralesional curettage in a femoral condyle location (recurrence model; n = 9 animals). For each animal, positive scans were analyzed at each time point using the target-to-background ratio (TBR), with the target region of interest delineated over the tumor and the background region of interest over muscle. In each model, the TBR time course was followed against primary tumoral growth or recurrence. Tumor volume was monitored for 2 mo by measuring the 2 perpendicular diameters. At study end, animals were sacrificed for histopathologic analysis.
RESULTS: For both models, (99m)Tc-NTP 15-5 scans showed tracer accumulation at the site of implantation or curettage. For the primary tumor model, the mean TBR was 1.6 +/- 0.14 by day 4 after implantation and increased over time as the disease progressed, with a mean TBR of 4.25 +/- 0.25 on day 45. For the recurrence model, mean TBR was 3.27 +/- 0.24 by day 4 after curettage and increased with recurrence, with a mean value of 5.25 +/- 0.49 on day 50. (99m)Tc-HMDP bone scans were negative for both models throughout the study; at a later stage of the study, an area of (99m)Tc-HMDP accumulation was seen in the diaphysis of the bone adjacent to the tumor and was attributed to remodeling.
CONCLUSION: These experimental results in 2 preclinical models of grade II chondrosarcoma bring forward data in favor of (99m)Tc-NTP 15-5 radiotracer for imaging primary growth of chondrosarcoma and its local recurrence after surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690026     DOI: 10.2967/jnumed.108.056721

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.

Authors:  Caroline Peyrode; Valérie Weber; Emmanuelle David; Aurélien Vidal; Philippe Auzeloux; Yves Communal; Marie Mélanie Dauplat; Sophie Besse; François Gouin; Dominique Heymann; Jean Michel Chezal; François Rédini; Elisabeth Miot-Noirault
Journal:  Invest New Drugs       Date:  2011-04-16       Impact factor: 3.850

2.  First ex vivo study demonstrating that 99mTc-NTP 15-5 radiotracer binds to human articular cartilage.

Authors:  Florent Cachin; Stéphane Boisgard; Aurélien Vidal; Marc Filaire; Philippe Auzeloux; Damien Culot; Serge Askienazy; Jean-Claude Madelmont; Jean-Michel Chezal; Elisabeth Miot-Noirault
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

3.  Patient specific respiratory motion modeling using a 3D patient's external surface.

Authors:  Hadi Fayad; Tinsu Pan; Olivier Pradier; Dimitris Visvikis
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

4.  Imaging technologies for preclinical models of bone and joint disorders.

Authors:  Jordi L Tremoleda; Magdy Khalil; Luke L Gompels; Marzena Wylezinska-Arridge; Tonia Vincent; Willy Gsell
Journal:  EJNMMI Res       Date:  2011-07-29       Impact factor: 3.138

5.  Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.

Authors:  Aurélien Voissiere; Valérie Weber; Yvain Gerard; Françoise Rédini; Florian Raes; Jean-Michel Chezal; Françoise Degoul; Caroline Peyrode; Elisabeth Miot-Noirault
Journal:  Oncotarget       Date:  2017-09-27

6.  99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model.

Authors:  Elisabeth Miot-Noirault; Emmanuelle David; Aurélien Vidal; Caroline Peyrode; Sophie Besse; Marie-Mélanie Dauplat; Marie-Françoise Heymann; François Gouin; Jean-Michel Chezal; Dominique Heymann; Françoise Rédini
Journal:  EJNMMI Res       Date:  2013-05-20       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.